|Direct||212 336 8117|
|Main||212 336 8000|
|Fax||212 336 8001|
Anne is a skilled advocate with 30 years’ experience advising clients on complex business litigation. Her practice has concentrated on intellectual property involving a wide range of technologies, with a particular focus on pharmaceutical and medical device patent litigation, including Hatch-Waxman ANDA matters. She has handled all phases of complex litigation from inception through resolution, and has extensive jury trial experience.
Anne works closely with clients to devise strategy and achieve business goals. Skilled at developing effective working relationships with senior executives and business units, she is able to clearly communicate the technology at issue to the fact finder in litigation.
She has a strong commitment to the training and development of other lawyers. Anne has served in leadership roles in deposition and trial skills training programs, and made numerous CLE presentations to practitioners.
Anne’s representations include successfully preventing Pronova Biopharma Norge AS from blocking Teva Pharmaceutical’s marketing of its generic Lovaza® product, in which Teva prevailed on appeal by invalidating the patent under the on-sale bar, and in preventing G.D. Searle and Pfizer Asia from blocking Teva’s marketing of its generic Celebrex® product, in which the district court found the patent invalid. Her other patent litigation cases include: representing Teva in all phases of Hatch-Waxman ANDA litigations involving a wide range of pharmaceuticals; Gillette on razor blade edge technology; Lucent on semiconductor technology and optical lasers; and Verizon on cellular technologies.
Anne divides her time between the firm and NYU School of Law, where she is a fulltime Research Scholar and Executive Director of the Engelberg Center on Innovation Law & Policy.